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Summary 173 
Accurate pathological diagnosis is crucial for optimal management of cancer patients. For the 174 
~100 known central nervous system (CNS) tumour entities, standardization of the diagnostic 175 
process has been shown to be particularly challenging - with substantial inter-observer 176 
variability in the histopathological diagnosis of many tumour types. We herein present the 177 
development of a comprehensive approach for DNA methylation-based CNS tumour 178 
classification across all entities and age groups, and demonstrate its application in a routine 179 
diagnostic setting. We show that availability of this method may have substantial impact on 180 
diagnostic precision compared with standard methods, resulting in a change of diagnosis in 181 
up to 12% of prospective cases. For broader accessibility we have designed a free online 182 
classifier tool (www.molecularneuropathology.org) requiring no additional onsite data 183 
processing. Our results provide a blueprint for the generation of machine learning-based 184 
tumour classifiers across other cancer entities, with the potential to fundamentally transform 185 
tumour pathology. 186 
  187 
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Main Text 188 
The developmental complexity of the brain is reflected in the vast array of distinct brain tumour entities 189 
defined in the current WHO classification of central nervous system (CNS) tumours 1. These tumours 190 
are clinically and biologically highly diverse, encompassing a wide spectrum from benign neoplasms 191 
that can frequently be cured by surgery alone (e.g. pilocytic astrocytoma), to highly malignant tumours 192 
responding poorly to any therapy (e.g. glioblastoma). Previous studies reported substantial inter-193 
observer variability in the histopathological diagnosis of many CNS tumours, e.g., in diffuse gliomas 2, 194 
ependymomas 3 and supratentorial PNETs 4. To address this, some molecular grouping has been 195 
introduced into the update of the WHO classification, but only for selected entities such as 196 
medulloblastoma. Furthermore, several single-gene tests based on DNA methylation analysis (e.g., 197 
MGMT promoter methylation status), FISH (e.g., 1p/19q, EGFR, MYC, MYCN, PDGFRA, 19q13.42, 198 
etc.) or immunohistochemistry (CTNNB1, LIN28A, etc.) that are required to cover the most important 199 
differential diagnoses have been shown to be difficult to standardize. Such diagnostic discordance and 200 
uncertainty may confound decision-making in clinical practice as well as the interpretation and validity 201 
of clinical trial results.  202 
The cancer methylome is a combination of both somatically acquired DNA methylation changes and 203 
characteristics reflecting the cell of origin 5,6. The latter property allows, for example, tracing of the 204 
primary site of highly dedifferentiated metastases of cancers of unknown origin 7. It has been 205 
convincingly shown that DNA methylation profiling is highly robust and reproducible even from small 206 
samples and poor quality material 8, and such profiles have been widely used to subclassify CNS 207 
tumours that were previously considered homogeneous diseases 4,9-16. Based on this preliminary work 208 
within single entities, we herein present a comprehensive approach for DNA methylation-based 209 
classification of all CNS tumour entities across age groups. 210 
 211 
CNS tumour reference cohort 212 
To establish a comprehensive CNS tumour reference cohort, we generated genome-wide DNA 213 
methylation profiles (minimum of eight cases per group) representing almost all WHO defined 214 
neuroectodermal and sellar region tumours 1. We further profiled mesenchymal tumours, melanoma, 215 
diffuse large B-cell lymphoma, plasmacytoma and six types of pituitary adenomas, in total comprising 216 
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76 histopathological entities and seven entity variants occurring in the CNS. All histopathological 217 
entities and variants were analysed by unsupervised clustering both within each entity and across 218 
histologically similar tumour entities, aiming to identify (i) distinct DNA methylation classes within one 219 
histopathological entity and (ii) DNA methylation classes comprising tumours displaying a varied 220 
histological phenotype. This iterative process led to the designation of 82 CNS tumour classes 221 
characterised by distinct DNA methylation profiles (Figure 1a). Twenty-nine of these were equivalent 222 
to a single WHO entity (category 1), 29 represented subclasses within a WHO entity (category 2), in 223 
eight the WHO grading was not fully recapitulated (category 3) and in 11 the boundaries of methylation 224 
classes were not identical to the entity boundaries of WHO (category 4) (Figure 1a). The remaining 225 
five represented DNA methylation classes not defined by the WHO classification (category 5), three of 226 
which were recently described 4 as well as the not yet well-defined class of anaplastic pilocytic 227 
astrocytoma and one new subclass of infantile hemispheric glioma. There was evidence for several 228 
additional classes of rare tumours, with too few cases to be included at present. In consideration of the 229 
impact of the tumour microenvironment on the methylation profile, we included 47 tumour samples 230 
with a pronounced inflammatory or reactive tumour microenvironment, respectively, both 231 
demonstrating distinct methylation profiles. We additionally selected 72 samples representing seven 232 
non-neoplastic CNS regions, resulting in a combined reference cohort of 2,801 samples from 91 233 
classes (Figure 1a) that was visualized using t-SNE dimensionality reduction 17 (Figure 1b). This 234 
analysis further supported the separation of samples into the defined DNA methylation classes (see 235 
also Extended Data Figure 1a, b; unprocessed .idat files can be downloaded at NCBIs Gene 236 
Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo), accession number GSE90496). 237 
Supplementary Table 1 gives an overview of methylation class characteristics and Supplementary 238 
Table 2 shows case-by-case information of the reference samples.  239 
The stability of separation of methylation classes by t-SNE was analysed by iterative random 240 
downsampling of the reference cohort and indicated a high stability of the groups (Extended Data 241 
Figure 1c, d). Testing for confounding batch effects within our reference cohort did not reveal 242 
unexpected confounding factors (Extended Data Figure 2, Extended Data Figure 3a-c). For reference 243 
astrocytomas, oligodendrogliomas and glioblastomas we performed additional classification according 244 
to the TCGA pan glioma DNA methylation model18 indicating a strong association of the TCGA classes 245 
LGm1-6 with specific classes defined in our reference cohort (Extended Data Figure 3d, 246 
Supplementary Table 2).  247 
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 248 
Classifier development 249 
Application in routine diagnostics requires fast and reproducible classification of samples as well as a 250 
measure of confidence for the specific call. To this end, we employed the Random Forest (RF) 251 
algorithm that is a so called ensemble method that combines the predictions of several 'weak' 252 
classifiers to achieve improved prediction accuracy19. Using this algorithm, we generated 10,000 253 
binary decision trees, incorporating genome-wide information from all 2,801 reference samples and 91 254 
methylation classes (Extended Data Figure 4). Each of these trees assigns a given diagnostic sample 255 
to one of the 91 classes, resulting in an aggregate raw score (Figure 2a). To obtain class probability 256 
estimates that can be used to guide diagnostic decision-making, we fitted a multinomial logistic 257 
regression calibration model that transforms the raw score into a probability that measures the 258 
confidence in the class assignment (‘calibrated score’). The calibration allows a comparison of 259 
classifier results between classes despite a different raw score distribution (Extended Data Figure 5a, 260 
b). Cross-validation of the RF classifier resulted in an estimated error rate of 4.89% for raw and 4.28% 261 
for calibrated scores and an area under receiver operating characteristic curve (AUC) of 0.99, 262 
indicating a high discriminating power (Figure 2b, Extended Data Figure 5c). The vast majority of 263 
cross-validation misclassifications occurred within eight groups of histologically and biologically closely 264 
related tumour classes, distinction of which is currently without clinical impact (with the possible 265 
exception of choroid plexus tumours 13; Figure 2b). We therefore defined eight ‘methylation class 266 
families’ (MCF), for which calibrated scores are summed up to a single score. This reduced the cross-267 
validated error rate for the clinically relevant groupings to 1.14% (Figure 2b, Extended Data Figure 5c). 268 
Taking the maximum score for class assignment and using a multiclass approach 20, overall sensitivity 269 
and specificity was 0.989 and 0.999, respectively (Extended Data Figure 5c).  270 
For application to diagnostic tumour samples, a threshold value for the prediction of a matching class 271 
is required. Using Receiver Operating Characteristic (ROC) curve analysis of the maximum calibrated 272 
scores we devised an optimal "common" calibrated score threshold of ≥0.9 (Extended Data Figure 5d, 273 
e). For subclasses within methylation class families, we defined a threshold value of ≥0.5 as sufficient 274 
for a valid prediction, as long as all family member scores add up to a total score of ≥0.9. Single class 275 
specificity and sensitivity for the ≥0.9 threshold are provided in Supplementary Table 3. 276 
 277 
Clinical implementation 278 
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For evaluation of clinical utility, we prospectively analysed a series of 1,155 diagnostic CNS tumours in 279 
parallel with standard histopathological workup (Figure 3a, b). For 51 cases (4%) the material was not 280 
suitable for methylation profiling, mostly because of too low tumour cell content or limited total 281 
material. Methylation profiling was performed for the remaining 1,104 samples and the cases were 282 
assigned as either ‘matching to a defined DNA methylation class’ (calibrated score ≥0.9) or as ‘no 283 
match’ cases (highest score <0.9) (for a case-by-case list see Supplementary Table 4). The 284 
investigated cases comprised 64 different histopathological entities from both adult (71%) and 285 
paediatric patients (29%). The spectrum of entities was enriched for rare and difficult to diagnose 286 
cases received for referral, and therefore did not exactly match the distribution seen in daily routine 287 
diagnostic practice. Histopathological evaluation was performed blinded to DNA methylation profiling 288 
results and included standard molecular testing.  289 
In total, 88% of profiled samples (n=977/1,104) matched to an established DNA methylation class with 290 
a calibrated classifier score ≥0.9 (Figure 3b). For 838 of these (838/1,104; 76%), results obtained by 291 
pathology and DNA methylation profiling were concordant. In 171 of the cases, an unambiguous 292 
molecular subgroup could be assigned, which would not have been available based on histopathology 293 
evaluation only (e.g., molecular subgroups of medulloblastoma and ependymoma, many of which 294 
were included in the latest version of the WHO classification of CNS tumours 1).  295 
For the remaining 139 samples with a calibrated classifier score ≥0.9, the DNA methylation class was 296 
discordant from the pathological diagnosis. These cases were histologically and molecularly re-297 
evaluated, including additional molecular diagnostics (DNA copy-number profiling, targeted gene 298 
sequencing, gene panel sequencing21, and gene fusion analysis of a subset of cases, see 299 
Supplementary Table 5). This resulted in a revision of the initial histopathological diagnosis in 129 of 300 
the 139 cases (12% of all cases, Figure 4) in favour of the predicted methylation class. In agreement 301 
with several recent reports 16,22,23, several of these were IDH-wildtype astrocytomas and anaplastic 302 
astrocytomas reclassified as IDH-wildtype glioblastomas. Establishing a new diagnosis had a profound 303 
clinical impact: a change in WHO grading was observed in 71% of these cases (92/129), with both 304 
upgrading (41%, 53/129) and downgrading (30%, 39/129; Figure 4). Discrepant results could not be 305 
resolved in only 10 cases (<1% of profiled cases), and the histopathological diagnosis was retained. 306 
To substantiate the impact in clinical practice we contacted five external centres that have started to 307 
implement methylation profiling for diagnostic cases using our algorithm. In total, these centres 308 
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analysed 401 diagnostic cases and in 50 cases (12%) a new diagnosis was established after 309 
methylation profiling, very closely recapitulating our rate of reclassification (Extended Data Figure 6a, 310 
Supplementary Table 6). For individual centres the rate of reclassification varied between 6% and 311 
25%, most likely due to differences of the spectrum of investigated cases and more upfront molecular 312 
testing by some centres (Extended Data Figure 6b, Supplementary Table 6). 313 
Twelve percent of tumours from the prospective cohort (127/1,104) could not be assigned to a DNA 314 
methylation class using the rigid calibrated classifier score cutoff of ≥0.9 (Figure 3b). To further clarify 315 
the role of these non-classifiable cases we performed an unsupervised t-SNE analysis of the reference 316 
cohort together with the diagnostic cohort (Figure 5a). This demonstrated a high overlap of the 317 
classifiable cases with the reference cohort, whereas non-classifiable cases frequently fell in the 318 
periphery of the reference classes or even completely separate from these and frequently grouped 319 
with other non-classifiable cases (Figure 5a). This may indicate that such cases represent rare novel 320 
molecular entities that have not been previously recognized. An example for a likely novel CNS tumour 321 
entity is exemplified in Figure 5b, c.  322 
 323 
Technical and inter-laboratory testing 324 
Technical robustness of the RF classifier was investigated by inter-laboratory comparison. Results of 325 
two independent laboratories (starting from DNA extraction) were highly correlated, with only two of 53 326 
samples (4%) showing a classifier score slightly lower than 0.9 in one of the centres whereas all other 327 
cases were classified identically (Extended Data Figure 7a). Calculation of copy number profiles was 328 
also stable across laboratories (Extended Data Figure 7b). To ascertain forward compatibility with 329 
developing technologies, we further used the RF classifier to interrogate newer EPIC DNA methylation 330 
arrays and high-coverage whole-genome bisulfite sequencing data. For all 16 samples from different 331 
CNS tumours profiled on both array platforms, raw scores (Extended Data Figure 7c) and calibrated 332 
scores (not shown) were highly correlated and running them through the classifying algorithm resulted 333 
in the same prediction for every case. Further, for all 50 high-coverage whole-genome bisulfite 334 
sequencing samples (11 different CNS tumour entities), the highest prediction score was for the same 335 
class as with the 450k array, suggesting that our approach is applicable to different DNA methylation 336 
profiling techniques with only slight adaptations (Extended Data Figure 7d). 337 
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 338 
Global dissemination of the platform 339 
To ensure unrestricted community access to our classification system, we created a free web platform 340 
for data upload, automatic normalization, Random Forest classification, and PDF report generation 341 
(www.molecularneuropathology.org). DNA copy-number profiles24 and O6-methylguanine-DNA-342 
methyltransferase (MGMT) promoter methylation status25 are additionally provided, since they can be 343 
generated from the same data source – thus having the potential of replacing several time- and cost-344 
intensive single-gene tests. A representative website report is shown in Extended Data Figure 8. 345 
During upload, the data provider can chose to give consent that the data may be used for further 346 
classifier development. We expect that this web platform can thereby act as a hub for a worldwide 347 
cooperative network to continuously identify and track rare tumour classes so that they can eventually 348 
be added to the catalogue of known human cancers. Since the launch of the website 14 months ago in 349 
December 2016, over 4,500 cases have been uploaded from over 15 participating centres. New 350 
biological insights are also likely to be gained based on the interrelationships of tumour classes, and 351 
by closer examination of how differential DNA methylation affects tumour biology.  352 
 353 
Discussion 354 
We here demonstrate that DNA methylation-based CNS tumour classification using a comprehensive 355 
machine learning approach is a valuable asset for clinical decision making. In particular, the high level 356 
of standardization has great promise to reduce the substantial inter-observer variability observed in 357 
current CNS tumor diagnostics. Further, in contrast to traditional pathology, whereby there is a 358 
pressure to assign all tumours to a described entity even for atypical or challenging cases, the 359 
objective measure that we provide here allows for 'no match' to a defined class. This information can 360 
also be of substantial value in highlighting that a tumour is not a typical example of a given differential 361 
diagnosis, and may rather belong to a rarer, yet undefined class. We defined 5 categories of 362 
methylation classes that have different clinical implications. Category 1 can be directly translated to 363 
WHO entities. Category 2 represents subclasses of WHO entities. For all but ependymal tumours, 364 
subclassification currently has little clinical consequence and a translation back to the WHO class may 365 
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be appropriate for clinical purposes. Category 3 reflects the fact that WHO grading cannot be fully 366 
recapitulated by methylation profiling for several classes. Further data is required to assess if the 367 
methylation classes of this category may provide a more robust means of prognostication than 368 
histology alone, as has been demonstrated for several other classes 4,9,11. In category 4, the WHO 369 
entity boundaries are not identical to the boundaries of the methylation classes. Until additional data 370 
on the exact boundaries become available, this category should be critically discussed in the clinical 371 
context and orthogonal testing should be undertaken whenever possible. Category 5 represents 372 
putative new entities that are currently not recognized by the WHO, and while limited data on these 373 
cases is currently available, the biological rationale for a novel class was considered strong. 374 
A study in which reference pathology and molecular diagnostics including DNA methylation profiling 375 
are blinded for each other´s results is currently ongoing for all childhood brain tumours diagnosed in 376 
Germany to objectivise the potential effect of re-classification on patient outcome (http://pediatric-377 
neurooncology.dkfz.de/index.php/en/diagnostics/molecular-neuropathology), with results due over the 378 
next few years.  379 
A uniform implementation of the classification algorithm holds great promise for standardization of 380 
tumour diagnostics across centres and across clinical trials. Further, the digital nature of methylation 381 
data facilitates easy exchange and will allow aggregation of extensive tumour libraries. This will likely 382 
result in the detection of exceptionally rare tumour classes and a continued refinement of classifiers. 383 
Inclusion of new classes will allow a prompt translation into diagnostic practice, almost certainly 384 
resulting in a more dynamic tumour classification. In our experience, adaptation of this technique in 385 
diagnostic laboratories is relatively straightforward. Extended Data Figure 9 summarizes a sample 386 
workflow for diagnostic implementation. We expect that the principle of using DNA methylation 387 
signatures as part of a combined histo-molecular tumour classification will improve diagnostic 388 
accuracy not only in neuropathology, but will serve as a blueprint in other fields of tumour pathology 389 
  390 
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Figure legends 391 
Figure 1 | Establishing of the DNA methylation-based CNS tumour reference cohort. a, Overview 392 
of the 82 CNS tumour methylation classes and nine control tissue methylation classes of the reference 393 
cohort. The methylation classes are grouped by histology and color-coded. Category 1 methylation 394 
classes are equivalent to a WHO entity, category 2 methylation classes are a subgroup of a WHO 395 
entity, category 3 methylation classes are not equivalent to a unique WHO entity with combining of 396 
WHO grades, category 4 methylation classes are not equivalent to a unique WHO entity with 397 
combining of WHO entities, and category 5 methylation classes are not recognized as a WHO entity. 398 
Full names and further details of the abbreviated 91 classes are given in Supplementary Table 1. 399 
Embryonal tumours: shades of blue; Glioblastomas: shades of green; Other gliomas: shades of violet; 400 
Ependymomas: shades of red; Glio-neuronal tumours: shades of orange; IDH-mutated gliomas: 401 
shades of yellow; Choroid plexus tumours: shades of brown; Pineal region tumours: shades of mint 402 
green; Melanocytic tumours: shades of dark blue; Sellar region tumours: shades of cyan; 403 
Mesenchymal tumours: shades of pink; Nerve tumours: shades of beige; Haematopoietic tumours: 404 
shades of dark purple; Control tissues: shades of grey. b, Unsupervised clustering of reference cohort 405 
samples (n=2,801) using t-SNE dimensionality reduction. Individual samples are colour-coded in the 406 
respective class colour (n=91) and labelled with the class abbreviation. The colour code and 407 
abbreviations are identical to Figure 1a. 408 
 409 
Figure 2 | Development and cross-validation of the DNA methylation-based CNS tumour 410 
classifier. a, Schematic of principal classifier components (grey) and processing steps for individual 411 
diagnostic samples (white). The most informative probes are selected for training of the Random 412 
Forest classifier. The classifier produces raw scores representing the number of decision trees 413 
assigning a diagnostic sample to a specific methylation class. To enable inter-class-comparability a 414 
calibration model is used, which transforms raw into calibrated scores. Calibrated scores represent an 415 
estimated probability measure of methylation class assignment. b, Heatmap showing results of a 416 
three-fold cross-validation of the Random Forest classifier incorporating information of n=2801 417 
biologically independent samples allotted to 91 methylation classes. Deviations from the bisecting line 418 
represent misclassification errors (using the maximum calibrated score for class prediction). 419 
Methylation class families (MCF) are indicated by black squares. The colour code and abbreviations 420 
are identical to Figure 1a.  421 
 422 
Figure 3 | Implementation of the classifier in diagnostic practice. a, Classifier validation by an 423 
independent prospective cohort of diagnostic samples. Pathological diagnosis was established by 424 
current pathological standard according to the 2016 version of the WHO classification of CNS tumours 425 
and compared to classification by methylation profiling. Cases were categorized as “confirmation of 426 
diagnosis”, “establishing new diagnosis”, “misleading profile”, or “no match to defined class”. b, 427 
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Overview of methylation profiling result from 1,155 diagnostic samples and integration with 428 
pathological diagnosis.  429 
Figure 4 | Reassessment of discrepant cases and establishment of new diagnosis. Discrepancy 430 
between pathological diagnosis (left) and methylation profiling (middle) was observed for 139 cases. 431 
For 129 cases histological and molecular reassessment (Supplementary Table 5) resulted in change 432 
of the initial diagnosis with formulation of a new integrated diagnosis (right). For 92 cases this involved 433 
change of WHO grading, with both down- (blue) and upgrading (red). Integrated diagnoses in brackets 434 
are not recognized as a WHO entity. For methylation class abbreviations see Supplementary Table 1. 435 
 436 
Figure 5 | DNA methylation-based identification of potential new CNS tumour entities. a, 437 
Unsupervised clustering of the combined reference (n=2,801, grey) and diagnostic cohort (n=1,104, 438 
coloured) using t-SNE dimensionality reduction. Abbreviated names indicate the reference cohort 439 
classes as in Figure 1. The diagnostic samples are colour coded as “confirmation of diagnosis” 440 
(n=838, green), “establishing new diagnosis” (n=129, blue), “misleading profile” (n=10, red) and “no 441 
match to defined class” (n=127, dark grey). The matching (green) and reclassified (blue) cases show 442 
high overlap with the reference cases. The non-classifiable (black) and the misleading (red) cases 443 
frequently fall in the periphery of the reference classes or are completely separate of these. The 444 
magnification (right) highlights two non-classifiable cases (here in magenta for easier identification) 445 
that group together in the t-SNE representation. b, Both highlighted non-classifiable cases occurred in 446 
female children, and had primitive neuroectodermal histology (glioblastoma- or embryonal tumour-447 
like). Histology was assessed by three independent pathologists with similar results. c, Both cases 448 
shared a high-level amplification of chromosome 6q24.2 (common amplified region chr6:144,149,293-449 
144,649,987). The common region includes only 5 protein coding genes: LTV1 (LTV1 ribosome 450 
biogenesis factor), ZC2HC1B (zinc finger C2HC-type containing 1B), PLAGL1 (PLAG1 like zinc finger 451 
1), SF3B5 (splicing factor 3b subunit 5) and STX11 (syntaxin 11). This amplification was not observed 452 
in any of the other tumours from the reference or diagnostic cohort. Copy number analysis was 453 
performed once using copy number information deriving from the methylation array data.  454 
 455 
  456 
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Methods (online only) 457 
Patient material 458 
Patient material and clinical data of the retrospective reference cohort (total n=2,801) were obtained 459 
from the National Center for Tumour Diseases (NCT) in Heidelberg and supplemented with samples 460 
from additional centres (Supplementary Table 2) according to protocols approved by the institutional 461 
review boards with written consent obtained from each patient. Tumours were histopathologically re-462 
assessed according to the current WHO classification1. Areas with highest tumour cell content (≥70%) 463 
were selected for DNA extraction. Subsets of the reference cohort have been previously published4,9-464 
16,26-33. Additional patient characteristics are given in Supplementary Table 2. The prospectively 465 
assessed clinical cohort was analysed as part of the National Center for Tumour Diseases Precision 466 
Oncology Program according to procedures approved by the institutional review board at the Medical 467 
Faculty Heidelberg. All patients gave written consent for diagnostic procedures, comprising onward 468 
molecular testing including methylation profiling. Additional patient characteristics are given in 469 
Supplementary Table 4. Details of the online-analysed cohort of the five additional centres are given in 470 
Supplementary Table 6. Usage of the data was according to protocols approved by the institutional 471 
review boards of the University of Basel, Frankfurt am Main University Hospital, University Medical 472 
Center Utrecht and Princess Máxima Center for Pediatric Oncology Utrecht, Giessen University 473 
Hospital and University College London Hospitals. All patients gave written consent for diagnostic 474 
procedures, comprising onward molecular testing including methylation profiling. For all the above 475 
human research participants all relevant ethical regulations were followed.  476 
 477 
 478 
Data generation, processing and Random Forest classifier generation 479 
Samples were analysed using Illumina Infinium HumanMethylation450 BeadChip (450k) arrays 480 
according to the manufacturer’s instructions. To investigate stability across platforms a selection of 481 
samples were additionally assessed using the successor Methylation BeadChip (EPIC) array or whole-482 
genome bisulfite sequencing (WGBS, generated and analysed as described6). Array data analysis 483 
was performed using R version 3.2.0 34, using a number of packages from Bioconductor35 and other 484 
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repositories. A Random Forest19 classifier compatible with both 450k and EPIC platforms was trained, 485 
and a calibration model that calculates class probabilities from Random Forest scores was devised. A 486 
detailed description of all methods is provided below.  487 
 488 
Methylation array processing 489 
The 450k array was used to obtain genome-wide DNA methylation profiles for tumour samples and 490 
normal control tissues, according to the manufacturer’s instructions (Illumina, San Diego, USA). DNA 491 
methylation data was generated at the Genomics and Proteomics Core Facility of the DKFZ 492 
(Heidelberg, Germany) and the NYU Langone Medical Center (New York, USA). Data was generated 493 
from both fresh-frozen and formalin-fixed paraffin-embedded (FFPE) tissue samples. For most fresh-494 
frozen samples, >500 ng of DNA was used as input material. 250 ng of DNA was used for most FFPE 495 
tissues. On-chip quality metrics of all samples were carefully controlled. Copy-number variation (CNV) 496 
analysis from 450k methylation array data was performed using the conumee Bioconductor package 497 
version 1.3.0. Two sets of 50 control samples displaying a balanced copy-number profile from both 498 
male and female donors were used for normalization. 499 
Raw signal intensities were obtained from IDAT-files using the minfi Bioconductor package version 500 
1.14.0 36. Each sample was individually normalized by performing a background correction (shifting of 501 
the 5 % percentile of negative control probe intensities to 0) and a dye-bias correction (scaling of the 502 
mean of normalization control probe intensities to 10,000) for both colour channels. Subsequently, a 503 
correction for the type of material tissue (FFPE/frozen) was performed by fitting univariate, linear 504 
models to the log2-transformed intensity values (removeBatchEffect function, limma package version 505 
3.24.15). The methylated and unmethylated signals were corrected individually. Estimated batch 506 
effects were also used to adjust diagnostic samples or test samples within the cross-validation. Beta-507 
values were calculated from the retransformed intensities using an offset of 100 (as recommended by 508 
Illumina). To analyse for possible confounding batch effects within our pre-processed reference cohort 509 
dataset (after adjusting for FFPE versus frozen material) we applied the sva algorithm 37,38. We found 510 
no significant surrogate variable (data not shown). 511 
The following filtering criteria were applied: Removal of probes targeting the X and Y chromosomes 512 
(n=11,551), removal of probes containing a single-nucleotide polymorphism (dbSNP132 Common) 513 
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within five base pairs of and including the targeted CpG site (n=7,998), probes not mapping uniquely 514 
to the human reference genome (hg19) allowing for one mismatch (n=3,965), and probes not included 515 
on the Illumina EPIC array (n=32,260). In total, 428,799 probes targeting CpG sites were kept for 516 
further analysis. 517 
 518 
Unsupervised analysis 519 
Pairwise Pearson correlation was calculated for all 2,801 reference samples by selecting the 32,000 520 
most variably methylated probes (s.d. > 0.228, Extended Data Figure 1a). The same probes were 521 
used for principal component analysis (PCA). For PCA, pairwise probe covariances of centred beta-522 
values were calculated. Eigenvalue decomposition was performed using the eigs function of the 523 
RSpectra package version 0.12. The number of non-trivial components was determined by comparing 524 
eigenvalues to the maximum eigenvalue of a PCA using randomized beta-values (shuffling of sample 525 
labels per probe) (Extended Data Figure 1b). Principal component scores for all non-trivial 526 
components (n=94) were used for t-SNE analysis (t-Distributed Stochastic Neighbour Embedding17, 527 
Rtsne package version 0.11, Figure 1b). The following non-default parameters were used: theta=0, 528 
pca=F, max_iter=2500. A similar approach was used for the combined analysis of reference and 529 
diagnostic cases (Figure 5a).  530 
 531 
The Random Forest algorithm 532 
The Random Forest (RF) 19 algorithm is a so-called ensemble method that combines the predictions of 533 
several 'weak' classifiers to achieve improved prediction accuracy. The RF algorithm uses binary 534 
decision trees (Classification and Regression Trees, CART39) as 'weak' classifiers (Extended Data Fig. 535 
4). Each of these trees is a sequence of binary splitting rules that are learned by recursive binary 536 
splitting. The CART algorithm starts with all samples assigned to a 'root' node and tries to find the 537 
variable, e.g., a measured CpG probe, and a corresponding cutoff that results in the purest split into 538 
the different classes. To measure this gain in class 'purity' the Gini index is used. To fit a tree, the 539 
CART algorithm iteratively repeats these steps until no further improvements can be made. To predict 540 
the class of a new diagnostic case the binary splitting rules are compared with the new data starting in 541 
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the root node down to one of the leaf nodes. The tree then predicts or votes for the class of that leaf 542 
node. Decision trees have the advantage that they are non-parametric and do not rely on any 543 
distributional assumptions. The main disadvantages of decision trees is that they often tend to overfit 544 
the data and that they have a weak prediction performance. To improve the prediction accuracy the 545 
RF algorithm combines thousands of trees by bootstrap aggregation (bagging). In brief, each tree is 546 
fitted using training datasets that are generated by drawing bootstrap samples. In addition, at each 547 
node only a random subset of the available variables is used to find an optimal splitting rule. This 548 
additional source of randomization allows selecting variables with lower predictive value. This feature 549 
guarantees that the resulting trees are decorrelated, i.e., they use different variables to find an optimal 550 
prediction rule. Taking the majority vote over thousands of bootstrap aggregated and decorrelated 551 
trees greatly improves the prediction accuracy of the RF. The majority vote, i.e., the proportion of trees 552 
voting for a class, can be interpreted as empirical class probabilities. 553 
 554 
Classifier development 555 
To train the RF classifier, the randomForest R package 40 was used. First, the most important features 556 
(probes) were selected by applying the Random Forest algorithm to the beta-values of all filtered 557 
428,799 probes. For efficient computation, the probes were split into 43 sets of approximately 10,000 558 
probes. For each set, 100 trees were fitted using 654 randomly sampled candidate features at each 559 
split (mtry parameter, square root of 428,799, as would be used by default when not splitting into sets). 560 
To take the imbalanced methylation class sizes into account a downsampling strategy was followed 561 
that ensures an identical number of samples per class (parameter sampsize=rep(8, 91)), eight 562 
reflecting the minimum number of cases in the 91 classes) 41. For all other parameters the default 563 
settings were used. This procedure was repeated 100 times, essentially fitting 10,000 trees per probe. 564 
Finally, features are selected by the permutation-based variable importance measure as implemented 565 
in the randomForest R package40. The importance measure is the class-specific mean decrease in 566 
classification accuracy when the feature is permutated. We select features by ranking them using the 567 
minimal rank of the variable importance measures across all classes.  568 
The final RF classifier was trained by fitting 10,000 trees with the parameter mtry=100 using beta-569 
values of the 10,000 probes selected during feature selection. Imbalanced class sizes were accounted 570 
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for by downsampling (as described above), and for all other parameters the default settings were 571 
used. An overview of the processes is given in Extended Data Fig. 4. 572 
 573 
Classifier cross-validation 574 
Overfitting of the training data is a typical problem expected when training classifiers on high-575 
dimensional data. As it often cannot be avoided, the typical strategy to deal with this problem is to 576 
evaluate the model accuracy on an independent test dataset or apply cross-validation methods42. 577 
Because some of the newly defined methylation groups presented in this work cannot be diagnosed 578 
by classical histopathological methods or other established molecular assays, an independent test set 579 
to assess model accuracy is not available. Therefore, the accuracy of the presented RF model with the 580 
accompanying calibration model was evaluated by a three-fold, nested cross-validation (CV). For this, 581 
the reference dataset is split into three equally sized parts. In each CV iteration, two-thirds of the data 582 
were used to train a RF classifier in the same way as the RF classifier for the complete dataset was 583 
trained. Then, the remaining one-third of the data is predicted using this RF classifier. After the third 584 
iteration of the CV is completed, each of the 2,801 reference samples has been predicted by an 585 
independent RF classifier, i.e. where the sample was not used for estimating batch effects, performing 586 
variable selection, or training of the classifier.  587 
 588 
Classifier score calibration 589 
The classification scores generated by our multiclass RF (i.e. the proportion of trees voting for a class) 590 
perform well when they are used to assign the correct class labels, but they do not reflect class 591 
probabilities. Furthermore, the distribution of the RF scores varies between classes, which makes an 592 
inter-class comparison difficult. Moreover, to evaluate a diagnostic classification, the uncertainties 593 
associated with an individual prediction in terms of confidence scores or estimated class probabilities 594 
are needed.  595 
To obtain scores that are comparable between classes and that are improved estimates of the 596 
certainty of individual predictions we performed a classification score recalibration by mapping the 597 
original scores to more accurate class probabilities43,44. To find such a mapping, a L2-penalized, 598 
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multinomial, logistic regression-model was fitted, which takes the methylation class as response 599 
variable and the RF scores as explanatory variables. The R package glmnet45 was used to fit this 600 
model. In addition, the model was fitted by incorporating a small ridge-penalty (L2) on the likelihood to 601 
prevent from over fitting, as well as to stabilize estimation in situations where classes are perfectly 602 
separable. The amount of this regularization, i.e. the penalization parameter, is determined by running 603 
a ten-fold cross-validation and choosing the largest value that lies within one standard error of the 604 
minimum cross-validation error. Independent RF scores are needed to fit this model, i.e. the scores 605 
need to be generated by a RF classifier that was not trained using the same samples, otherwise the 606 
RF scores will be systematically biased and not comparable to scores of unseen cases. As such, RF 607 
scores generated by the three-fold CV are used. 608 
To validate the class predictions generated by using the recalibrated scores of the calibration model, a 609 
nested three-fold CV loop is incorporated into the main three-fold CV that validates the RF classifier 610 
(Extended Data Fig. 4). Within each CV run this nested three-fold CV is applied to generate 611 
independent RF scores, which are then used to train a calibration model. The predicted RF scores 612 
resulting from predicting the one-third test data of the outer CV loop are then recalibrated by applying 613 
the calibration model that was fitted on the RF scores generated during the nested CV. A similar CV 614 
scheme was used by Appel et al.46 to validate estimated classification probabilities.  615 
 616 
Classifier performance measures 617 
Performances of the resulting classifier predictions and scores generated by the CV were assessed by 618 
the misclassification error, multiclass area under the curve (AUC) and the multiclass Brier score. The 619 
misclassification error measures the frequency of falsely assigned class labels when using the 620 
maximum of the RF scores or re-calibrated scores as a cutoff to determine the predicted class, i.e. the 621 
majority vote. To measure the AUC for our multiclass RF the generalization of the AUC for multiclass 622 
classification problems by Hand and Till47 was used. To measure how well the resulting RF scores and 623 
recalibrated scores perform when used as class probabilities, the multiclass Brier Score42,48,49 was 624 
used. The Brier score is the mean-squared difference between the actual and the predicted class 625 
probability and thus measures the same characteristic as the mean squared error (MSE) measures for 626 
a continuous forecast. 627 
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 628 
Methylation class families 629 
We observed that the majority of misclassification errors occurred within eight groups of histologically 630 
and biologically closely related tumour classes. We therefore defined eight ‘methylation class families’ 631 
(MCF). Since calibrated scores represent class probabilities, it is possible to apply the addition rule of 632 
probabilities to sum up calibrated class scores within one MCF to get a class probability for the MCF. 633 
 634 
Threshold analysis 635 
Finding an optimal cutoff for diagnostic tests usually involves finding an optimal trade-off between 636 
sensitivity and specificity. If there are no preferences regarding specificity or sensitivity, the optimal 637 
cutoff is chosen by the upper left corner of the ROC curve or by maximizing the Youden index 638 
(specificity+sensitivty-1). In an application like the one described here, where the cost of false negative 639 
is that a tumour cannot be classified and the cost of a false positive is a falsely predicted methylation 640 
class, a threshold with high specificity is preferred. ROC analysis is typically defined for binary 641 
classification problems. Finding a threshold for multiclass classifiers either involves performing a ROC 642 
analysis for each class resulting in class-wise individual thresholds or finding some common threshold 643 
for all classes. 644 
The calibrated MC/MCF scores (here referring to MCF and MC classes that are not assigned to a 645 
MCF) are already validated probability estimates for the methylation class with a direct interpretation, 646 
i.e. we expect among all samples with scores of approx. 0.9 that 10% are falsely predicted. Applying 647 
an additional threshold is not required from a statistical point of view, but desired in clinical practice. In 648 
addition, due to calibration, scores are comparable across classes and it is thus reasonable to define a 649 
common threshold for all classes instead of finding optimal cutoff for each individual methylation class. 650 
To determine a common threshold for the calibrated MC/MCF scores, we performed a ROC analysis 651 
of the maximum calibrated MC/MCF scores calculated via cross-validation. For this ROC analysis we 652 
defined a new binary class, i.e. samples correctly classified during the CV using the maximum 653 
calibrated MC/MCF score for classification were considered as 'classifiable' and samples falsely 654 
classified by using this score were considered 'non-classifiable'.  655 
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Following this ROC analysis approach, we determined a cutoff of 0.836 that maximises the Youden 656 
index with a specificity of 93.8% and sensitivity of 93.4% (Extended Data 5d and e). A maximum 657 
specificity of 100% with a sensitivity of 82.7% can be achieved with a threshold of 0.958. Bootstrapped 658 
95% confidence intervals (grey area in Extended Data Figure 5d) demonstrate the uncertainty of 659 
sensitivity and specificity estimates, especially in the left upper corner of the ROC figure, where the 660 
considered thresholds are located. 661 
Both thresholds have been determined by cross-validation on our training data of high quality, but real 662 
life diagnostic samples were found to achieve slightly lower scores, due to a number of factors we 663 
cannot control, such as lower overall sample quality and lower tumour purity compared to samples in 664 
our reference cohort. Therefore, we decided to lower the maximum specificity threshold to allow a 665 
wider spectrum of samples to become a match. For this, we chose a threshold of ≥0.9 that lies in the 666 
middle between the Youden index and the threshold for maximum specificity.  667 
 668 
Comparison to TCGA pan-glioma methylation classes 669 
To compare our methylation-based classification of CNS tumours with described methylation classes 670 
of brain tumours by the Cancer Genome Atlas (TCGA) project, we downloaded the pre-processed 671 
methylation dataset described in Ceccarelli et al. 201618 including methylation data of 418 low grade 672 
glioma and 377 glioblastoma samples analysed by using the Illumina 450k array or 27k array 673 
platforms. To classify our samples according to the TCGA pan-glioma DNA methylation classification, 674 
we trained a Random Forest classifier on this dataset using the 1,300 CpG probe signature provided 675 
by the authors and using the default settings of the Random Forest algorithms implemented in the R 676 
package randomForest. The results of this classification for astrocytomas, oligodendrogliomas and 677 
glioblastomas are shown in Extended Data Figure 3d and are given on a case-by-case basis in 678 
Supplementary Table 2 and 4.  679 
 680 
Estimating tumour purity from DNA methylation data 681 
Due to the subjective nature of histological assessment of tumour purity, we additionally used the 682 
Ceccarelli et al. 2016 dataset18 to train a Random Forest regression (continuous response variable) 683 
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model to predict tumour purity50. This Random Forest was trained on the 1,000 most important CpG 684 
probes for purity estimation selected also by a Random Forest (similar to the variable selection 685 
described for the Random Forest classifier). The out-of-bag (i.e. RF trees in which the respective 686 
sample, for which purity is predicted, was not used for training) mean squared error of the final model 687 
is 0.015, indicating that this model is able to yield reasonable predictions of tumour purity from 688 
methylation data (Extended Data Figure 3a-c). The estimated tumour purity for individual cases is 689 
given in Supplementary Table 2 and 4.  690 
 691 
Code availability 692 
The generated code is available from the corresponding author (S.M.P.) on reasonable request for 693 
non-commercial use. 694 
 695 
Data Availability 696 
The complete methylation values required for the construction of the classifier (the reference cohort) 697 
have been deposited in NCBIs Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo). 698 
The accession number is GSE90496. Supplementary Table 2 includes the IDAT-file names for 699 
assignment to patient characteristics. The methylation data of the prospective cohorts are available on 700 
request from the corresponding author (S.M.P.). The data are not publicly available due to them 701 
containing information that could compromise research participant privacy/consent. Source data for 702 
Figure 1b, 2b, 3b, 4, 5a,c and Extended Data Figure 1c, 2a-f, 3a-d, 5a,b,d,e, 6 and 7a,c,d are provided 703 
with the paper.  704 
  705 
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 875 
Extended data figure legends 876 
Extended Data Figure 1 | Unsupervised clustering of the DNA methylation-based reference 877 
cohort. a, Heatmap showing the pairwise Pearson correlation (lower left) of the 32,000 most variably 878 
methylated CpG probes of all 2,801 biologically independent samples of the reference cohort. A 879 
detailed view on closely related ependymal classes (upper right) and the three subclasses identified in 880 
ATRT tumours (lower right) indicates higher correlation within classes. The colour code and 881 
abbreviations are identical to main Figure 1a. b, Barplot showing eigenvalue frequencies of a principal 882 
component analysis (PCA) using the same 32,000 most variably methylated CpG probes of all 2,801 883 
biologically independent samples as in (a). The number of non-trivial components were determined by 884 
comparing eigenvalues to the maximum eigenvalue of a PCA using randomized beta-values (shuffling 885 
of sample labels per probe). c, X and Y coordinates of the first five of a total of 500 iterations of t-SNE 886 
dimensionality reduction generated by random downsampling to 90% of the 2,801 biologically 887 
independent samples to assess clustering stability. Axis positions of individual cases are connected by 888 
a line coloured according to the colour code of Figure 1a. The depiction illustrates the close proximity 889 
of cases of the same class across iterations, indicative of a high stability independent of the exact 890 
composition of the reference cohort. d, Pairwise correlation of X and Y coordinates between 2,801 891 
biologically independent samples over all iterations of the downsampling analysis demonstrates a very 892 
high correlation within classes (average correlation 0.982), indicating a high stability of the t-SNE 893 
analysis. 894 
 895 
Extended Data Figure 2 | Unsupervised clustering is not biased by a range of possible 896 
confounding factors. a, t-SNE representations of the 2,801 biologically independent samples 897 
constituting the reference cohort as shown in Figure 1b overlaid with potentially confounding factors 898 
(b-f). b, Distribution of patient sex among the classes illustrates equal or near equal distribution of 899 
many classes, but also an expected enrichment for one sex in some classes (e.g. female in 900 
meningioma or CNS high-grade neuroepithelial tumour with MN1 alteration). c, Patient age illustrates 901 
the expected age distribution of many tumour classes. d-f, The slightly uneven distribution of type of 902 
material (e.g. pilocytic astrocytoma or meningioma) (d), array preparation date (e), and tissue source 903 
(f) are related to the specifics of assembling the reference cohort and do not indicate an apparent 904 
confounding effect on the unsupervised clustering. 905 
 906 
Extended Data Figure 3 | Estimation of tumour purity and relation to TCGA pan-glioma 907 
methylation classes. a, A Random Forest model was trained to predict ABSOLUTE tumour purity 908 
estimates50 using the TCGA pan-glioma dataset (795 biologically independent samples)18. The plot 909 
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shows ABSOLUTE purity estimates and out-of-bag Random Forest tumour purity predictions (i.e. 910 
using only RF trees for which the respective sample was not involved in the training). The estimated 911 
mean squared error is 0.015, indicating that this model is able to yield reasonable predictions of 912 
tumour purity from methylation data. b, Bar plot showing the distribution of Random Forest predicted 913 
purity in the reference dataset (2,801 biologically independent samples). Purity estimates have been 914 
transformed into five categories indicated by different shades of blue. The exact case-by-case values 915 
are given in Supplementary Table 2. The median estimated purity in the reference cohort is 66% 916 
(range 42% to 87%) and 78% of samples have an estimated purity of at least 60%. c, t-SNE 917 
representation of the reference cohort (2,801 biologically independent samples) overlayed with 918 
Random Forest predicted purity categories. Methylation classes are generally composed of mixed 919 
tumour purity categories. Tumour purity shows some association with the WHO grade (WHO I median 920 
tumour purity 60%, range 39-77%; WHO II median 66%, range 43-80%; WHO III median 68% range 921 
54-84%; WHO IV median 69% range 49-87%). A further association of tumour purity with the 922 
composition of classes in the unsupervised t-SNE analysis was not evident. d, t-SNE representation of 923 
the reference cohort (2,801 biologically independent samples) overlayed with predicted TCGA pan-924 
glioma DNA methylation classes according to Ceccarelli et al. 2016. Pan-glioma methylation classes 925 
were predicted by training a Random Forest (RF) on the Ceccarelli et al. 2016 dataset including 926 
methylation data of 418 low grade glioma and 377 glioblastoma samples acquired using the Illumina 927 
450k and 27k platforms. The RF was trained using the 1,300 CpG signature as described by the 928 
authors18 and using the default settings of the RF algorithm implemented in the R package 929 
randomForest. Pan-glioma class prediction was only performed for subsets of mostly adult 930 
astrocytomas, oligodendrogliomas and glioblastomas (magnified areas) included in the Ceccarelli et 931 
al. 2016 data set. LGm1, LGm2 and LGm3 show a high overlap with the methylation classes A IDH 932 
HG, A IDH and O IDH, respectively. LGm4 shows highest overlap with methylation class GBM RTK II. 933 
LGm5 shows highest overlap with methylation classes GBM MES and GBM RTK I. LGm6 show 934 
highest overlap with DMG K27, GBM MID and GBM MYCN. 935 
 936 
Extended Data Figure 4 | Development of the Random Forest classifier. a, The RF training 937 
consists of four steps. First, a basic filtering for probes that are not included on the EPIC array, probes 938 
located on the X and Y- chromosomes, probes affected by SNPs, and probes not mapping uniquely to 939 
the genome is performed. In a second step, the probe-wise batch effects between samples from FFPE 940 
and frozen material are estimated and adjusted by a linear model approach. In a third step, feature 941 
selection is performed by training a RF using all probes and selecting the 10,000 probes with highest 942 
variable importance measure. In a last step, the final RF is trained using only the 10,000 selected 943 
probes. The validation of the RF classifier involves a three-fold nested cross-validation (CV). In the 944 
outer loop of the CV the complete RF training procedure described before is applied to the training 945 
data and the resulting RF is used to predict the test data to generate RF scores. In the inner loop of 946 
the CV a three-fold CV is applied to training data of the outer loop in order to generate RF scores 947 
independent of the test data in the outer loop. These scores are then used to fit a calibration model, 948 
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i.e. a L2-penalized, multinomial, logistic regression that takes the RF scores of the test data in the 949 
outer CV loop to estimate tumour class probabilities (P1, P2, P3). To fit a calibration model to estimate 950 
class probabilities of diagnostic samples using all data in the reference set, the RF scores generated 951 
in the outer CV loop are used. b, Schematic depiction of three exemplary binary decision trees of the 952 
Random Forest classifier (left), and magnification on five exemplary decisions nodes relevant for 953 
glioblastoma classification (right). For prediction, a diagnostic sample enters the root node of each of 954 
the 10,000 trees. At every decision node, the decision path is determined on the methylation level of a 955 
single CpG, until reaching a terminal node that provides the class prediction. The joint class prediction 956 
of all trees represents the raw prediction score. The colour code and abbreviations are identical to 957 
Figure 1a. 958 
 959 
Extended Data Figure 5 | Comparison of raw and calibrated classifier scores and threshold 960 
definition. a, Density plots illustrating the distribution of raw and calibrated classifier scores for 961 
samples correctly classified during cross-validation (n=2,701 independent biological samples for raw 962 
and n=2769 independent biological samples for calibrated), depicted for each methylation class or 963 
methylation class family (MCF). Score calibration results in a harmonization of score distribution and 964 
allows the establishment of a shared classification threshold. Three thresholds for maximizing 965 
specificity (0.958), maximizing the Youden index (0.836), and the cutoff used in this study (0.9) are 966 
indicated by red lines (see also panels d and e). b, Multivariate score calibration exemplified in a 967 
ternary plot showing scores of the three ATRT subclasses (MYC, SHH, and TYR; together n=112 968 
independent biological samples). Arrows indicate transformation of the scores for individual samples 969 
by the calibration model, which increases the discrimination between the three subclasses. c, The 970 
accuracy of prediction of the Random Forest classifier constructed of n=2801 biologically independent 971 
samples (measured by misclassification error, area under receiver operating characteristic curve 972 
(AUC), Brier score, multiclass Sensitivity and Specificity) is improved by score calibration and by 973 
combining classes into methylation class families (MCF). d, To determine a common threshold for the 974 
calibrated MCF scores, we performed a Receiver Operating Characteristic (ROC) analysis of the 975 
maximum calibrated MCF scores of all n=2801 biologically independent samples calculated via cross-976 
validation. For this ROC analysis we defined a new binary class, i.e. samples correctly classified 977 
during the CV using the maximum calibrated MCF score for classification were considered as 978 
'classifiable' (n=2769) and samples that got falsely classified by using this score were considered 'non 979 
classifiable' (n=32). Three thresholds for different sensitivity and specificity are highlighted in the ROC 980 
curve: A threshold of 0.958 achieving a maximum specificity of 1 with a sensitivity of 0.827, a threshold 981 
of 0.836 obtaining a maximum Youden index with Specificity 0.938 and sensitivity 0.934, and our 982 
recommended compromise threshold of 0.9 that results in a specificity of 0.938 and a sensitivity of 0.9. 983 
Bootstrapped 95% confidence intervals for estimated sensitivity and specificity are indicated in grey. e, 984 
Sensitivity and specificity for all possible thresholds applied to cross-validated maximum MCF 985 
classifier scores of all n=2801 biologically independent samples. Three thresholds for maximizing 986 
specificity (0.958), maximizing the Youden index (0.836) and 0.9 are highlighted by red lines. 987 
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 988 
Extended Data Figure 6 | Diagnostic utility of the DNA-methylation based classifier, assessed 989 
at different centres. a, Implementation of the DNA methylation classifier by five external centres. In 990 
total, 401 independent biological samples were analysed. 78% matched to an established class with a 991 
cut-off score of ≥0.9 (class colours as in Figure 1a). A new diagnosis was established in 12% of cases. 992 
b, Depiction of individual centre results, illustrating the different composition of samples included in the 993 
analysis, variation in the rate of non-matching cases, and of cases where a new diagnosis was 994 
established. Case-by-case details are given in Supplementary Table 6. 995 
 996 
Extended Data Figure 7 | Inter-centre and inter-platform reproducibility of DNA methylation-997 
based classification. a, Calibrated scores of 53 independent biological samples representing 998 
diagnostic CNS tumour cases analysed at the University of Heidelberg and at the New York University 999 
pathology department. Both laboratories performed independent DNA extraction, array hybridization, 1000 
and data analysis. Cases falling into green areas were classified identically in both centres (96%); 1001 
cases in the red area were non-classifiable in one centre (4%). None of the 53 samples was assigned 1002 
to a different methylation class by the two centres. b, Copy-number profiles calculated from the array 1003 
data generated at both centres were highly comparable and allowed identification of chromosomal 1004 
gains, losses, amplifications, and deletions. Calculations and interpretation were performed once at 1005 
each centre. c, Plot of maximum raw classification scores of 16 different tumour samples generated 1006 
using both 450k and EPIC arrays. All cases fall close to the bisecting line (red) indicating a high 1007 
concordance of the scores. Further, the methylation class prediction was identical for all samples. d, 1008 
The CNS tumour classifier also performs well with data generated by whole-genome bisulfite 1009 
sequencing (WGBS). The plot shows classifier scores calculated from WGBS and 450k arrays of 50 1010 
cases comprising 11 different brain tumour entities (bisecting line in red). Methylation beta-values 1011 
were calculated from high-coverage WGBS data (>10 fold average coverage) and run through the 1012 
CNS tumour classifier and plotted against the same case analysed using 450k arrays. The highest 1013 
class prediction score was identical in all cases.  1014 
 1015 
Extended Data Figure 8 | Sample website PDF report of a IDH wildtype glioblastoma sample. 1016 
Extended Data Figure 9 | Exemplary workflow and timeline of diagnostic methylation profiling. 1017 
 1018 
Supplementary Table Legends 1019 
 1020 
Supplementary Table 1 | Overview of reference methylation class characteristics. This table 1021 
gives an overview of the main characteristics of the 82 tumor and 9 non-tumor methylation classes 1022 
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including full names of the methylation class, association of class with a methylation class family, 1023 
number of cases per class, class age characteristics, male / female ratio, tumor localization, most 1024 
frequent pathological diagnoses and a running text summarizing typical class features. Further, the 1025 
Hex colour code of the reference classes used throughout this manuscript is provided. 1026 
 1027 
Supplementary Table 2 | Case by case list of reference cohort. This table gives case-by-case 1028 
details of the n=2801 biologically independent samples constituting the reference cohort including the 1029 
Sentrix ID (.idat), tissue source, clinical data, methylation class and technical specifications.  1030 
 1031 
Supplementary Table 3 | Single class sensitivity and specificity. This table provides single class 1032 
specificity and sensitivity for the ≥0.9 calibrated classifier score for methylation class families and 1033 
methylation classes that are not assigned to a methylation class family. In addition single class 1034 
specificity and sensitivity is provided for the ≥0.5 calibrated classifier score for methylation classes that 1035 
are part of a methylation class family and that can be used for subclassification for individual family 1036 
member identification. The data was generated using n=2801 biologically independent samples.  1037 
 1038 
 1039 
Supplementary Table 4 | Case by case list of prospective cohort. This table gives case-by-case 1040 
details of the n=1104 biologically independent samples constituting the prospective clinical cohort 1041 
including information on the tissue source, clinical data, methylation class prediction, interpretation of 1042 
classification and technical specifications. 1043 
 1044 
Supplementary Table 5 | Case by case list of of discordant cases. This table gives case-by-case 1045 
details of the n=139 biologically independent samples with discordant results between pathological 1046 
diagnosis and methylation profiling. The cases are categorized into reclassified ("establishing new 1047 
diagnosis", n=129) or misleading profile (n=10). Information on the orthogonal methods used for 1048 
reassessment as well as the key information resulting in reclassification is provided. 1049 
 1050 
Supplementary Table 6 | Case by case list of external diagnostic cohort. This table gives case-by-1051 
case details of the n=401 biologically independent samples constituting the external centre diagnostic 1052 
cohort including clinical data, original pathological diagnosis, methylation class prediction, 1053 
interpretation of classification and the final pathological diagnosis (after integration with classifier 1054 
result).  1055 
 1056 
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a Reference cohort (91 classes) b t-SNE dimensionality reduction (2,801 samples)
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